404 related articles for article (PubMed ID: 27250825)
61. New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
Sasser JM
Kidney Int; 2014 Jul; 86(1):9-10. PubMed ID: 24978374
[TBL] [Abstract][Full Text] [Related]
62. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo.
McDonald GA; Sarkar P; Rennke H; Unemori E; Kalluri R; Sukhatme VP
Am J Physiol Renal Physiol; 2003 Jul; 285(1):F59-67. PubMed ID: 12820641
[TBL] [Abstract][Full Text] [Related]
63. Elastin metabolism in pelvic tissues: is it modulated by reproductive hormones?
Chen B; Wen Y; Yu X; Polan ML
Am J Obstet Gynecol; 2005 May; 192(5):1605-13. PubMed ID: 15902165
[TBL] [Abstract][Full Text] [Related]
64. Relaxin abrogates genomic remodeling of the aged heart.
Romero G; Salama G
Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
[TBL] [Abstract][Full Text] [Related]
65. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
Hewitson TD; Ho WY; Samuel CS
Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
[TBL] [Abstract][Full Text] [Related]
66. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
67. Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts.
Mookerjee I; Unemori EN; DU XJ; Tregear GW; Samuel CS
Ann N Y Acad Sci; 2005 May; 1041():190-3. PubMed ID: 15956706
[TBL] [Abstract][Full Text] [Related]
68. Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and -2 during uterine and cervical growth and remodeling in the pig.
Lenhart JA; Ryan PL; Ohleth KM; Palmer SS; Bagnell CA
Endocrinology; 2002 Jan; 143(1):91-8. PubMed ID: 11751597
[TBL] [Abstract][Full Text] [Related]
69. Targeted induction of collagenase and stromelysin by relaxin in unprimed and beta-estradiol-primed diarthrodial joint fibrocartilaginous cells but not in synoviocytes.
Kapila S; Xie Y
Lab Invest; 1998 Aug; 78(8):925-38. PubMed ID: 9714180
[TBL] [Abstract][Full Text] [Related]
70. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
[TBL] [Abstract][Full Text] [Related]
71. Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice.
Leo CH; Ou JLM; Ong ES; Qin CX; Ritchie RH; Parry LJ; Ng HH
Biomed Pharmacother; 2023 Jun; 162():114578. PubMed ID: 36996678
[TBL] [Abstract][Full Text] [Related]
72. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Sasser JM
Am J Physiol Regul Integr Comp Physiol; 2013 Sep; 305(6):R559-65. PubMed ID: 23883673
[TBL] [Abstract][Full Text] [Related]
73. Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases.
Lam M; Royce SG; Samuel CS; Bourke JE
Pharmacol Ther; 2018 Jul; 187():61-70. PubMed ID: 29447958
[TBL] [Abstract][Full Text] [Related]
74. Photonic monitoring in real time of vascular endothelial growth factor receptor 2 gene expression under relaxin-induced conditions in a novel murine wound model.
Ryan PL; Youngblood RC; Harvill J; Willard ST
Ann N Y Acad Sci; 2005 May; 1041():398-414. PubMed ID: 15956738
[TBL] [Abstract][Full Text] [Related]
75. Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.
Beiert T; Tiyerili V; Knappe V; Effelsberg V; Linhart M; Stöckigt F; Klein S; Schierwagen R; Trebicka J; Nickenig G; Schrickel JW; Andrié RP
Biochem Biophys Res Commun; 2017 Aug; 490(3):643-649. PubMed ID: 28634079
[TBL] [Abstract][Full Text] [Related]
76. Relaxin Modulates the Expression of MMPs and TIMPs in Fibroblasts of Patients with Carpal Tunnel Syndrome.
Kang YM; Lee HM; Moon SH; Kang H; Choi YR
Yonsei Med J; 2017 Mar; 58(2):415-422. PubMed ID: 28120574
[TBL] [Abstract][Full Text] [Related]
77. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
[No Abstract] [Full Text] [Related]
78. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
[TBL] [Abstract][Full Text] [Related]
79. Relaxin reverses inflammatory and immune signals in aged hearts.
Martin B; Gabris-Weber BA; Reddy R; Romero G; Chattopadhyay A; Salama G
PLoS One; 2018; 13(1):e0190935. PubMed ID: 29346407
[TBL] [Abstract][Full Text] [Related]
80. The pathogenesis of organ fibrosis: Focus on necroptosis.
Hao M; Han X; Yao Z; Zhang H; Zhao M; Peng M; Wang K; Shan Q; Sang X; Wu X; Wang L; Lv Q; Yang Q; Bao Y; Kuang H; Zhang H; Cao G
Br J Pharmacol; 2023 Nov; 180(22):2862-2879. PubMed ID: 36111431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
